Welcome to our dedicated page for Abpro Holdings SEC filings (Ticker: ABPWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Abpro Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Abpro Holdings's regulatory disclosures and financial reporting.
Abpro Holdings, Inc. entered into an unsecured $147,000 loan agreement with its Chief Executive Officer and Chairman, Miles J.W. Suk, to pay the premium for its directors’ and officers’ liability insurance. The CEO will pay the insurer or broker directly, and the funds may be used only for that insurance cost.
The loan runs for nine months and can be repaid early without penalty. No interest is charged for the first three months after funding; after that, the outstanding principal bears interest at a variable rate equal to three-month Term SOFR plus 2.0% per year, with interest due at maturity or earlier repayment. The loan is unsecured and not guaranteed by any third party.
On January 16, 2026, director Ian McDonald resigned from Abpro’s board and all board committees, with the company stating his resignation was not due to any disagreement over operations, policies, or practices. The board appointed Dr. Byung-Hak Yoon as a Class I director to fill the vacancy, with a term ending at the 2028 annual meeting, and named him to the Audit, Compensation, and Nominating and Corporate Governance Committees. Dr. Yoon, age 51, brings extensive leadership experience in biotechnology and medical companies and will receive the company’s standard compensation for independent directors.